BlueRock Therapeutics will continue to operate as an independent company with a focus on developing cell therapies in neurology, cardiology, and immunology.
Organizations Involved
Bayer AG, Versant Ventures
Company Description
BlueRock Therapeutics is a biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology using a proprietary induced pluripotent stem cell (iPSC) platform. Bayer will fully acquire BlueRock Therapeutics, with an initial focus in neurology, cardiology, and immunology.